Literature DB >> 11559527

Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.

F Bullrich1, H Fujii, G Calin, H Mabuchi, M Negrini, Y Pekarsky, L Rassenti, H Alder, J C Reed, M J Keating, T J Kipps, C M Croce.   

Abstract

Chromosome 13q14 deletions constitute the most common genetic abnormality in chronic lymphocytic leukemia (CLL). To identify the putative tumor suppressor gene targeted by 13q14 genomic loss, we completely sequenced and characterized a segment of 790 kb at 13q14 spanning the minimal region of loss in CLL. Transcribed sequences in the region were identified through database homology searches and exon-prediction analysis. Two-hundred kb at the centromeric end of the sequence contain five CpG islands, three previously identified genes LEU5/RFP2, LEU2, and LEU1, seven of seven EST clusters composed of >10 ESTs, and a large number of predicted exons. Homology searches against the mouse EST database have allowed us to identify a highly conserved alternative first exon of the LEU2 gene, giving rise to a novel transcript, ALT1 (GenBank accession no. AF380424), which originates within a G+C region in the vicinity of the D13S272 marker. Two novel 3' exons of LEU2 were also identified and are present in both LEU2 and ALT1 transcripts. However, we have not identified any mutations in leukemia cases, or alterations in expression of mRNAs in the region, that might directly implicate these mRNAs in the pathology of CLL. The centromeric end of the sequence, where all reported genes are located, contains twice the expected amount of ALU repeats, whereas the telomeric end is LINE1 rich and contains four LINE1 elements longer than 4 kb, including two full-length LINE1 sequences. This feature of the sequence may favor the occurrence of chromosomal rearrangements and may confer instability to the region, resulting in deletions that may inactivate an as yet unidentified tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559527

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

Review 2.  Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.

Authors:  George A Calin; Carlo M Croce
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene.

Authors:  Mario Acunzo; Giulia Romano; Dorothee Wernicke; Veronica Balatti; Laura Z Rassenti; Marie dell'Aquila; Thomas J Kipps; Yuri Pekarsky; Carlo M Croce
Journal:  Blood       Date:  2014-05-22       Impact factor: 22.113

4.  Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays.

Authors:  Jill M Hagenkord; Federico A Monzon; Shera F Kash; Stan Lilleberg; Qingmei Xie; Jeffrey A Kant
Journal:  J Mol Diagn       Date:  2010-01-14       Impact factor: 5.568

5.  The roles of microRNAs in tumorigenesis and angiogenesis.

Authors:  Weining Yang; Daniel Y Lee; Yaacov Ben-David
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-06-18

Review 6.  miR deregulation in CLL.

Authors:  Veronica Balatti; Yuri Pekarky; Lara Rizzotto; Carlo M Croce
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

7.  Exosomal lncRNAs as new players in cell-to-cell communication.

Authors:  Mihnea Dragomir; Baoqing Chen; George A Calin
Journal:  Transl Cancer Res       Date:  2018-03       Impact factor: 1.241

Review 8.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

9.  ARLTS1 polymorphisms and basal cell carcinoma of the skin.

Authors:  Xuchen Li; Andreas Gast; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

10.  Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).

Authors:  Katy Hanlon; Claudius E Rudin; Lorna W Harries
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.